We are reporting a case of a 55-year-old woman who was diagnosed as having a non-functioning pancreatic neuroendocrine neoplasm (NF-PNEN), the World Health Organization (WHO) low grade (G1) with liver metastases. In the staging process the Then, due to disease progression -radioisotope therapy with b-emitter Yttrium-90 ( 90 Y). Based on this experience and on the review of the literature, we recommend that the discrepancy between the imaging studies could be due to heterogeneity of proliferation rate and somatostatin receptors (SSTR) expression within a primary PNEN and metastases. Therefore in such cases of advanced PNEN WHO G1 in the lack of response to everolimus and octreotide LAR administration isotope therapy without a prior chemotherapy should be considered as a palliative treatment according to ESMO Clinical Practice Guidelines and Polish Network of Neuroendocrine Tumors.
Background
Pancreatic neuroendocrine neoplasms (PNENs WHO 1) are rare malignant diseases [1] . Due to frequently asymptomatic growth, the majority of PNENs are diagnosed at locally advanced or metastatic stage [2] . The role of surgery is therefore often palliative, whereas chemotherapy has limited activity [3] [4] [5] . Recent studies (RADIANT-2 and RADIANT-3) showed efficacy of everolimus with or without concurrent somatostatin analogue in low-or intermediate grade advanced PNENs and, therefore, it is recommended in first line therapy [6] [7] [8] . Everolimus, a 40-O-(2-hydroxyethyl) derivative of sirolimus, is an oral inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase that stimulates the cell growth, proliferation and angiogenesis [9] . So far, it has been used for the treatment advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib and in combination with steroidal aromatase inhibitor in hormone-receptor positive, human epidermal growth factor receptor type 2 (HER2) negative breast cancer, after failure of letrozole or anastrozole therapy [10, 11] . The gallium-DOTA-octreotate positron emission tomography -computer tomography ( 68 Ga-DOTATATE PET) allows visualization of somatostatin receptors type 2 (SSRT2), typically expressed in intermediate and well differentiated primary and metastatic PNENs [12] [13] [14] [15] , while the Positron Emission Computed Tomography PET-CT with 18F-fluorodeoxyglucose (F-FDG PET-CT) allows detecting sites of involvement of poorly differentiated PNENs.
Case report
A 55-year-old woman was admitted to the hospital in April 2012 with the head of pancreas tumor seen in triphasic computer 
Discussion
The classification and nomenclature of the neuroendocrine gastroenteropancreatic neoplasms (GEP NENs) is complex [4, 5] . After several modifications, the new WHO classification presented in 2010 separating well-differentiated PNENs into low-grade (G1) and intermediate grade (G2) categories and all poorly differentiated as neuroendocrine carcinoma (PNEC G3) [16] . This classification is based on histologic grading system using either mitotic counting or Ki67 labeling index. Nearly one-half of GEP NENs have a high heterogeneity of proliferation rate within a tumor (or among different sites of disease if metastases are present) [17] . Therefore, in order to better predict patient outcome, at least 40 high power fields should be counted for mitoses and/or Ki67 labeling index [17, 18] . Moreover, GEP NETs characterized by heterogeneity in the SSTR expression [19, 20] . The SSTR2 is most common in PNENs and therefore is used in the diagnosis and treatment [4, 5] . For obvious reasons, the proper diagnosis is more difficult if is based on material from core needle biopsy.
The use of everolimus vs. best supportive care in advanced PNENs (low-or intermediate grade) resulted in impressive increase of median progression free survival (11.4 vs 5.4 months, respectively); even though in most patients only disease stabilization or minor tumor shrinkage was achieved [8] . In that study, the treatment response was assessed by triphasic CT or magnetic resonance imaging every 12 weeks according RECIST 1.0 criteria, and all discrepancies between local and central assessments were verified by independent central adjudication board. However, recent data suggest that the RECIST criteria based on measurement of the longest diameter of all measurable lesions seen on axial CT may be suboptimal in assessing the therapy response in PNENs [21] . Similarly, F-FDG PET-CT may be ineffective for PNENs imaging, as typically only poorly differentiated, highly malignant PNENs show an increased FDG uptake [22] . Interestingly, in our case F-FDG PET showed an uptake in the pancreatic tumor despite its low grade, whilst metastatic lesions in the liver were not visible. It may be due to the above-mentioned SSRT2 expression and proliferation heterogeneity within a tumor or among metastases sites.
68
Ga-DOTATATE PET allows visualization of SSTR2, typically expressed in the intermediate and well differentiated primary and metastatic PNENs [12] [13] [14] [15] . This method seems to be more sensitive Case report than F-FDG PET-CT and magnetic resonance imaging in the initial staging of PNENs, response evaluation and follow-up [23, 24] . In our case, 68 Ga-DOTATATE PET allowed early detection of tumor progression in the liver.
Conclusions
The discrepancy between 68 Ga-DOTATATE PET, F-FDG PET-CT and CT imaging suggests the heterogeneity of proliferation and SSRT2 expression in PNENs. It seems that in such a case -advanced PNEN G1 in the lack of response to everolimus and octreotide LAR administration, isotope therapy without a prior chemotherapy should be considered as a palliative treatment according to ESMO Clinical Practice Guidelines and Polish Network of Neuroendocrine Tumors [4, 5] . The role of 68 Ga-DOTATATE PET in response assessment during PNENs treatment including everolimus therapy needs to be further determined. Further, so far there is no data regarding the relationship between SSTR2 expression and response to everolimus therapy.
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